Effective therapy for NASH is still lacking. In this study, we investigated the effects of Ursodeoxycholic acid (UDCA) in the treatment of NASH. Methods: Western and Chinese databases were ...
Ursodeoxycholic acid (UDCA) is widely used for the treatment of chronic cholestatic liver diseases. However, a recent randomized, controlled trial has surprisingly shown that the use of high-dose ...
Effect of ursodeoxycholic acid (UDCA) on survival. Comparison of proportion of patients surviving in the UDCA-treated group ( ), placebo group (- - - -), and predicated group using the Mayo risk model ...
New Delhi: The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has ...
Mirum Pharmaceuticals' promising pipeline and strong financials make it an attractive buy in the competitive PBC space. Click ...
GlobalData on MSN2mon
Intercept’s liver disease drug Ocaliva faces FDA approval delayIn September 2024, the EC gave Ipsen’s Iqirvo (elafibranor) the green light for the treatment of PBC in combination with ...
The FDA in 2016 granted accelerated approval to the farnesoid X receptor (FXR) agonist as a second-line treatment for adults with PBC, either in combination with ursodeoxycholic acid (UDCA ...
in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA. The final European Commission decision ...
U.S. Indication for Livdelzi Livdelzi is indicated for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have had an inadequate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results